SELB Selecta Biosciences Inc.

2.24
+0.2  (+10%)
Previous Close 2.04
Open 2.06
Price To Book 4.98
Market Cap 50336778
Shares 22,471,776
Volume 429,352
Short Ratio
Av. Daily Volume 478,635

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Head to head trial vs Krystexxa to be initiated 1Q 2019 with interim data due 4Q 2019 and full data 1Q 2020.
SEL-212
Tophaceous gout
Grade 5 SAE reported October 17, 2018.
SEL-403
Mesothelioma

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605545
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 19563977
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19556452
  4. 424B5 - Prospectus [Rule 424(b)(5)] 19540085
  5. 8-K - Current report 19540025
  6. 424B5 - Prospectus [Rule 424(b)(5)] 19535535
  7. 8-K - Current report 19535412
  8. 8-K - Current report 19512204
  9. 8-K - Current report 19505577
  10. 8-K - Current report 181212806